INBRAIN Neuroelectronics

About INBRAIN Neuroelectronics

INBRAIN Neuroelectronics is a clinical-stage neurotechnology company developing brain-computer interface (BCI) therapeutics based on graphene technology. The company was established in 2019, with some sources indicating a 2020 founding date, as a spin-off from the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and ICREA. Its founders include CEO Carolina Aguilar, a former Medtronic executive with extensive experience in neuromodulation; CSO Jose Antonio Garrido, an ICREA Research Professor at ICN2; and Professor Kostas Kostarelos, Chair of Nanomedicine at the University of Manchester and a leader at ICN2's Nanomedicine Lab. The company was born from research at the intersection of MedTech, DeepTech, and Digital Health, aiming to translate discoveries in materials science into advanced therapeutic applications. INBRAIN's core technology is an intelligent neural platform that uses ultra-thin, flexible graphene-based electrodes for the bidirectional decoding and modulation of brain activity. This technology is designed to offer significantly higher resolution compared to traditional metal electrodes, enabling more precise and personalized therapies. The implant, which is thinner than a human hair at just 10 micrometers thick, conforms to the brain's surface, ensuring high-fidelity signal recording and targeted stimulation. The system integrates machine learning and AI to interpret complex neural signals, identify biomarkers specific to certain conditions, and deliver adaptive, closed-loop neurostimulation to rebalance pathological neural networks. This approach aims to maximize therapeutic efficacy while minimizing side effects. The company's primary market focus is on neurological disorders. It received a Breakthrough Device Designation from the U.S. FDA in September 2023 for its Intelligent Network Modulation System as an adjunctive therapy for Parkinson's disease. INBRAIN is also targeting other conditions such as epilepsy and stroke rehabilitation. The company has achieved significant milestones, including the world's first human implantation of a graphene neural interface in a clinical trial evaluating the device's safety and performance during brain tumor resections. This study demonstrated the device's ability to safely interface with the human brain and record high-resolution neural signals. INBRAIN's business model is that of a venture-funded medtech startup focused on the development and commercialization of its BCI platform. It has successfully raised substantial capital, securing over $100 million in total funding through several rounds, including a $50 million Series B round in October 2024. Key investors include imec.xpand, Asabys Partners, and the EIC Fund. The company collaborates with leading research institutions, technology companies, and pharmaceutical firms, such as the University of Manchester, imec, Microsoft, and Merck, to advance its technology from clinical trials to commercial-scale manufacturing. Keywords: graphene neuroelectronics, brain-computer interface, BCI, neurotechnology, neuromodulation, precision neurology, Parkinson's disease, epilepsy, stroke rehabilitation, graphene electrodes, neural interface, bioelectronics, MedTech, clinical trials, FDA Breakthrough Device, deep brain stimulation, AI in healthcare, neural decoding, adaptive therapy, implantable devices, neurosurgery